True to form beautifully researched thank you Shellbell, I think PTX100 phase 2a results could be a catalyst for a chain of events. Of course, this depends on the 2a patient cohort results. But l am reasonably confident that our results should reach our PTX100 phase 1 patient results which would more than qualify. I am a SYC supporter and believe he played his role in the progress of the Company and had a background in Medical Science and Colins Street Banking. But he was not qualified to take us to the next level, and this is where the new CEO has the skills needed. JMcD has results on the board for achieving licensing agreements and has played a major role in multi-billion-dollar deals. Wise investors would be accumulating shares in PTX and taking advantage of the opportunity to purchase at this price level.
Add to My Watchlist
What is My Watchlist?
